FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115428578> ?p ?o ?g. }

• W2115428578 endingPage "23" @default.
• W2115428578 startingPage "15" @default.
• W2115428578 abstract "As part of an extensive clinical development programme in patients with type 2 diabetes (T2DM), vildagliptin 50 mg once daily and twice daily, and 100 mg once daily have been assessed in placebo-controlled and, more importantly, in head-to-head active-comparator monotherapy trials over a wide range of baseline HbA1c levels and in a large number of elderly patients. Notable findings in individual trials included: comparable HbA1c lowering over 24 weeks with 100 mg once daily or 50 mg twice daily; efficacy comparable to rosiglitazone with reduced risk of weight gain and oedema over 24 weeks; and durable glycaemic control for up to 2 years with a reduced frequency of gastrointestinal adverse events compared with metformin. Pooled monotherapy data indicate that vildagliptin 100 mg daily produces consistent and clinically meaningful reductions in HbA1c across a range of initial HbA1c levels, in patients with lower and greater body mass index, and in younger and older patients. To date, the safety/tolerability profile seems comparable to placebo with neutral effects on body weight and lipid profiles, and minimal risk of hypoglycaemia. A preliminary study in subjects with impaired glucose tolerance showed that vildagliptin 50 mg once daily enhanced islet cell function, reduced glycaemic excursions and was very well tolerated, paving the way for a future trial in diabetes prevention. Vildagliptin has also been extensively studied in multiple clinical scenarios as add-on combination therapy in patients with inadequate glycaemic control on metformin, thiazolidinedione, sulfonylurea and insulin treatment, and has consistently been shown to improve glycaemic control with good tolerability and low risk for hypoglycaemia. In a trial in patients receiving metformin, the addition of vildagliptin 50 mg twice daily resulted in a 1.1% reduction in HbA1c at 24 weeks. Compared with add-on pioglitazone 30 mg daily in patients inadequately controlled with ongoing metformin therapy, vildagliptin 50 mg twice daily reduced HbA1c by 0.9% vs. 1.0% and was not associated with weight gain (+0.3 kg vs. +1.9 kg) over 24 weeks. Most notably, vildagliptin plus pioglitazone as initial combination therapy in drug-naïve patients resulted in robust HbA1c reductions of 1.9% from baseline. In patients receiving stable insulin therapy, vildagliptin 50 mg twice daily improved glycaemic control and was associated with a significant reduction in hypoglycaemic episodes over 24 weeks. Vildagliptin shows considerable promise as a partner for metformin and other commonly used oral antidiabetic agents, and may well play an important role in combination with insulin therapy to further improve glycaemic control." @default.
• W2115428578 created "2016-06-24" @default.
• W2115428578 creator A5045489578 @default.
• W2115428578 creator A5050887800 @default.
• W2115428578 date "2008-02-05" @default.
• W2115428578 modified "2023-10-13" @default.
• W2115428578 title "Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes" @default.
• W2115428578 cites W1970406523 @default.
• W2115428578 cites W1970498822 @default.
• W2115428578 cites W1977619586 @default.
• W2115428578 cites W1984588810 @default.
• W2115428578 cites W1989976483 @default.
• W2115428578 cites W2020638064 @default.
• W2115428578 cites W2027249582 @default.
• W2115428578 cites W2038915028 @default.
• W2115428578 cites W2047353065 @default.
• W2115428578 cites W2119114384 @default.
• W2115428578 cites W2123355624 @default.
• W2115428578 cites W2153449155 @default.
• W2115428578 doi "https://doi.org/10.1111/j.1742-1241.2007.01692.x" @default.
• W2115428578 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18269437" @default.
• W2115428578 hasPublicationYear "2008" @default.
• W2115428578 type Work @default.
• W2115428578 sameAs 2115428578 @default.
• W2115428578 citedByCount "22" @default.
• W2115428578 countsByYear W21154285782012 @default.
• W2115428578 countsByYear W21154285782013 @default.
• W2115428578 countsByYear W21154285782014 @default.
• W2115428578 countsByYear W21154285782015 @default.
• W2115428578 countsByYear W21154285782017 @default.
• W2115428578 countsByYear W21154285782018 @default.
• W2115428578 countsByYear W21154285782020 @default.
• W2115428578 crossrefType "journal-article" @default.
• W2115428578 hasAuthorship W2115428578A5045489578 @default.
• W2115428578 hasAuthorship W2115428578A5050887800 @default.
• W2115428578 hasConcept C126322002 @default.
• W2115428578 hasConcept C134018914 @default.
• W2115428578 hasConcept C142724271 @default.
• W2115428578 hasConcept C197934379 @default.
• W2115428578 hasConcept C204787440 @default.
• W2115428578 hasConcept C27081682 @default.
• W2115428578 hasConcept C2776453732 @default.
• W2115428578 hasConcept C2777180221 @default.
• W2115428578 hasConcept C2778375690 @default.
• W2115428578 hasConcept C2778854520 @default.
• W2115428578 hasConcept C2779306644 @default.
• W2115428578 hasConcept C2780323712 @default.
• W2115428578 hasConcept C535046627 @default.
• W2115428578 hasConcept C555293320 @default.
• W2115428578 hasConcept C71924100 @default.
• W2115428578 hasConceptScore W2115428578C126322002 @default.
• W2115428578 hasConceptScore W2115428578C134018914 @default.
• W2115428578 hasConceptScore W2115428578C142724271 @default.
• W2115428578 hasConceptScore W2115428578C197934379 @default.
• W2115428578 hasConceptScore W2115428578C204787440 @default.
• W2115428578 hasConceptScore W2115428578C27081682 @default.
• W2115428578 hasConceptScore W2115428578C2776453732 @default.
• W2115428578 hasConceptScore W2115428578C2777180221 @default.
• W2115428578 hasConceptScore W2115428578C2778375690 @default.
• W2115428578 hasConceptScore W2115428578C2778854520 @default.
• W2115428578 hasConceptScore W2115428578C2779306644 @default.
• W2115428578 hasConceptScore W2115428578C2780323712 @default.
• W2115428578 hasConceptScore W2115428578C535046627 @default.
• W2115428578 hasConceptScore W2115428578C555293320 @default.
• W2115428578 hasConceptScore W2115428578C71924100 @default.
• W2115428578 hasLocation W21154285781 @default.
• W2115428578 hasLocation W21154285782 @default.
• W2115428578 hasOpenAccess W2115428578 @default.
• W2115428578 hasPrimaryLocation W21154285781 @default.
• W2115428578 hasRelatedWork W1996010611 @default.
• W2115428578 hasRelatedWork W2072752555 @default.
• W2115428578 hasRelatedWork W2081947250 @default.
• W2115428578 hasRelatedWork W2099305220 @default.
• W2115428578 hasRelatedWork W2108456334 @default.
• W2115428578 hasRelatedWork W2117762041 @default.
• W2115428578 hasRelatedWork W2120212319 @default.
• W2115428578 hasRelatedWork W2124465362 @default.
• W2115428578 hasRelatedWork W2401881665 @default.
• W2115428578 hasRelatedWork W4220781513 @default.
• W2115428578 hasVolume "62" @default.
• W2115428578 isParatext "false" @default.
• W2115428578 isRetracted "false" @default.
• W2115428578 magId "2115428578" @default.
• W2115428578 workType "article" @default.